BioNxt Solutions Advances in MS Treatment Study

BioNxt Solutions Inc., a leader in drug delivery technology, is preparing for a critical human bioequivalence study. Their product, BNT23001, a sublingual thin-film formulation of Cladribine, targets Multiple Sclerosis (MS). Internal and third-party data show it offers comparable absorption and bioequivalence to current oral tablets.

The company has acquired Cladribine active ingredient for collaboration with Gen-Plus, a European CRDO. The study, set in Munich, will last under 30 days. Updates on the study and Gen-Plus integration will follow.

BNT23001 aims to improve MS management by enhancing absorption and user convenience. It aligns with BioNxt’s mission to better chronic disease outcomes through advanced drug delivery systems.